Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sheila A Doggrell

Showing results (31-40 of 220) with videos related to

Pageof 22
Sort By:
Expert Opinion on Pharmacotherapy|August 28, 2004
Recent pharmacological advances in the treatment of preterm membrane rupture, labour and deliverySheila A Doggrell
Expert Opinion on Investigational Drugs|March 5, 2004
Is everolimus useful in preventing allograft rejection and vasculopathy after heart transplant?Sheila A Doggrell
Drug News & Perspectives|December 12, 2003
Cardiovascular research in AustraliaSheila A Doggrell
Current Clinical Pharmacology|August 12, 2008
Misoprostol for the treatment of early pregnancy failureSheila A Doggrell
Current Opinion in Lipidology|April 10, 2018
What have we learnt from the clinical outcomes trials with the cetrapibs?Sheila A Doggrell
Expert Opinion on Investigational Drugs|January 19, 2010
The hedgehog pathway inhibitor GDC-0449 shows potential in skin and other cancersSheila A Doggrell
Idrugs : the Investigational Drugs Journal|May 12, 2009
Ticagrelor, a platelet aggregation inhibitor for the potential prevention and treatment of arterial thrombosis and acute coronary syndromesSheila A Doggrell
Expert Opinion on Pharmacotherapy|October 13, 2007
Does rosiglitazone increase cardiovascular outcomes?Sheila A Doggrell
Expert Opinion on Pharmacotherapy|November 16, 2007
Which is the best primary medication for long-term smoking cessation--nicotine replacement therapy, bupropion or varenicline?Sheila A Doggrell
Expert Opinion on Investigational Drugs|June 25, 2009
Tesofensine--a novel potent weight loss medicine. Evaluation of: Astrup A, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1906-13Sheila A Doggrell
Pageof 22

Showing results (31-40 of 220) with videos related to

Sort By:
Pageof 22
Expert Opinion on Pharmacotherapy|August 28, 2004
Recent pharmacological advances in the treatment of preterm membrane rupture, labour and deliverySheila A Doggrell
Expert Opinion on Investigational Drugs|March 5, 2004
Is everolimus useful in preventing allograft rejection and vasculopathy after heart transplant?Sheila A Doggrell
Drug News & Perspectives|December 12, 2003
Cardiovascular research in AustraliaSheila A Doggrell
Current Clinical Pharmacology|August 12, 2008
Misoprostol for the treatment of early pregnancy failureSheila A Doggrell
Current Opinion in Lipidology|April 10, 2018
What have we learnt from the clinical outcomes trials with the cetrapibs?Sheila A Doggrell
Expert Opinion on Investigational Drugs|January 19, 2010
The hedgehog pathway inhibitor GDC-0449 shows potential in skin and other cancersSheila A Doggrell
Idrugs : the Investigational Drugs Journal|May 12, 2009
Ticagrelor, a platelet aggregation inhibitor for the potential prevention and treatment of arterial thrombosis and acute coronary syndromesSheila A Doggrell
Expert Opinion on Pharmacotherapy|October 13, 2007
Does rosiglitazone increase cardiovascular outcomes?Sheila A Doggrell
Expert Opinion on Pharmacotherapy|November 16, 2007
Which is the best primary medication for long-term smoking cessation--nicotine replacement therapy, bupropion or varenicline?Sheila A Doggrell
Expert Opinion on Investigational Drugs|June 25, 2009
Tesofensine--a novel potent weight loss medicine. Evaluation of: Astrup A, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1906-13Sheila A Doggrell
Pageof 22